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LETTERS TO THE EDITORBIOPROSTHETIC DURABILITY
ASSESSMENT: IMPORTANCE
OF COMPLETE DATA
To the Editor:
Myken and Bech-Hansen1 reported
a 20-year experience with the Biocor
valve (St Jude Medical, Inc, St Paul,
Minn). This study consisted of 1518
aortic valve replacements and 194 mi-
tral valve replacements (MVRs). The
predominant area of interest in the re-
port has been the durability of the
prosthesis in the mitral position. The
article reported on structural valve de-
terioration (SVD) as determined by
explant reoperation. The alternative
method of retrospective reporting is
to combine SVD by explant reopera-
tion and with SVD by clinical (echo-
cardiographic) evaluation. Myken
and Bech-Hansen1 reported echocar-
diographic performance but did not
include echocardiographic evaluation
in their durability analysis. Only
Kaplan–Meier actuarial data analysis
was reported, because their objective
was to report on prosthesis perfor-
mance and not performance in
a specific population subset (actual
cumulative incidence).
Myken and Bech-Hansen1 reported
promising results with respect to
MVR actuarial freedom from explant
reoperation for SVD. For patients
older than 65 years, the 20-year actu-
arial freedom from reoperation for
SVD in MVR was 88.0%. Two previ-
ous reports on MVR freedom from
reoperative SVD have illustrated sim-
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MVR populations with mean ages
of 48 and 49 years.2,3 Pomerantzeff
and colleagues3 in 2006 reported
favorable actuarial freedoms from
reoperation for SVD for MVR at
15 years of 88.7% for patients 51 to
60 years old and 84% for patients
61 to 80 years old. Kirali and col-
leagues2 reported in 2001 MVR actu-
arial freedom from reoperation for
SVD of 76.8% at 13 years. An im-
portant aspect of the latter publica-
tion is that the freedom from SVD
for all clinically documented cases
was 64.8% at 13 years (39 cases of
overall SVD vs 16 reoperative cases).
The distinctions in reporting of SVD
for MVR by the different definitions
are illustrated by Kirali and col-
leagues.2
Myken and Bech-Hansen1 reported
that for patients older than 65 years
undergoing aortic valve replacement
the 20-year actuarial freedom from re-
operation for SVD was 92.1%. In
2008, Eichinger and coauthors,4 in
a separate 20-year publication on the
Biocor prosthesis, reported actuarial
freedom from reoperation for SVD at
15 years of 90.6% for aortic valve re-
placement in a cohort of 455 patients
(mean age, 72.5  9 years). The actu-
arial freedom at 15 years for overall
SVD was 88.4%. Sixteen of 23 pa-
tients with SVD came to reoperation.
The actuarial freedom at 20 years
from reoperation for SVD was
86.5%. The distinctions in reporting
of SVD for aortic valve replacement
by the different definitions are illus-
trated by Eichinger and colleagues.4
The comparison of SVDs from var-
ious studies must always consider how
SVD is reported, either on the basis of
explant reoperation or on the basis of
a combination of explant reoperation
and clinical parameters. The currently
approved next generation of the Bio-
cor porcine bioprosthesis, the Epic
porcine bioprosthesis, needs durabil-
ity assessment, preferably combining
both methods of reporting SVD, by re-
operation explant and by reoperationardiovascular Surgery c February 2011explant combined with clinical (echo-
cardiographic) evaluation.
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We thank Drs Suyker and Leicher
for their comments1 regarding our
article reporting 20-year experience
of 1712 patients with the Biocor
(St Jude Medical, Inc, Minneapolis,
Minn) porcine bioprosthesis2 and
would like to respond. We agree that
one would wish for longer mean
follow-up; however, our study does
not differ significantly from other
20-year studies (Table 1).3-8 This
only reflects the increasing numbers
of bioprostheses inserted during this
period, a trend for the entire Western
world.
Suyker and Leicher1 are further
concerned that reporting actuarial
freedom from reoperation for struc-
tural valve deterioration (SVD) rather
than all SVD may underestimate
the impact of SVD. The difficulty is
that there is no specific definition
of SVD. All bioprostheses are gradu-
ally degenerating, and which valves
should categorize as affected by
SVD? Even if we had a consensus def-
inition, there is difficulty in obtaining
